IDIBELL on the media
The first device capable of activating a light-activated drug by remote control has been designed
A wireless device capable of remotely activating a photopharmaceutical with proven therapeutic effect has been designed
A new combined strategy to overcome immune resistance in metastatic uveal melanoma
The combination of tebentafusp and IL-2 could benefit metastatic uveal melanoma patients.
Honorary Diploma of the Catalan Society of Psychiatry and Mental Health for Dr. Jiménez-Murcia and Dr. Fernández-Aranda
The Catalan Society of Psychiatry and Mental Health has recognized the contribution of both professionals, national and international leaders in clinical psychology
New oral drug shows high efficacy in HER2-mutated lung cancer
Zongertinib could become a new tool in the treatment of HER-2 mutated lung cancer, specially for an specific group of patients
New study on the causes of severe COVID-19 in vaccinated patients
A type of autoantibodies is demonstrated to be an independent risk factor for the severity of COVID-19
Kleptomania: Bellvitge leads a new approach in the study and treatment of the disease
Kleptomania is described for the first time not only as an impulsive disorder, but also as a compulsive disorder.
Two new gene-editing tools have been created from microorganisms of the bottom of the ocean: Asterix and Obelix’s CRISPR
The new tools are highly efficient, operate at colder temperatures, and appear to be more specific than the canonical system.
Dr. Roser Velasco, co-lead author of an international guideline on the management of neurological complications in CAR-T cell treatments
Dr. Roser Velasco, IDIBELL principal investigator at Neuro-Oncology group and neurologist at the Neuro-Oncology Unit of ICO Hospitalet and Bellvitge University Hospital, has co-directed the writing of an international guide of recommendations on the management of neurological complications associated with CAR-T cell therapy. Dr. Velasco has participated as an expert in neuro-oncology within the Committee […]
Gene therapy reverses the symptoms of a rare neurological disease in animal models
Megaloencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare childhood disease that mainly affects the white matter of the brain. Among other symptoms, it is characterized by macrocephaly, inability to coordinate motor movements, and epilepsy. More than 75% of diagnosed cases are due to mutations in the MLC1 gene, which encodes a protein located in […]
